Generally, the scorecard ranked scores like a traffic light, with green, yellow, and red scores. The 26 companies produced 30 products: 4 products score green, 7 score yellow, but 19 products are in the red zone.
According to the results of a study released on Monday, the Company and their German partner BioNTech say that they gave children aged five to 11 years, a two-dose regimen of 10 μg (micrograms) which were administered 21 days apart. The dosage was selected as the preferred dose for safety and effectiveness in children.
Russia registered the vaccine for public use in August and became the first country to do so through a controversial approval that came in before the start of the large-scale trial in September.
The company notes in a press release that they have so far not observed any safety concerns and that they plan to ask the Food and Drug Administration for emergency authorization of the two-dose vaccine later this month, after it has collected the recommended two months of safety data.
The deal will help countries like Uganda, Nigeria, Rwanda, Kenya, Tanzania, Sudan, South Africa and Zimbabwe to save an average of 59 per cent for the 20 cancer medicines, which are used to treat breast, cervical and prostate cancer; the commonest cancers in Africa. They also cover childhood cancers.
